Morning trading March 17, page-36

  1. 27,780 Posts.
    lightbulb Created with Sketch. 104
    ATX Announcement: Amplia Completes Single Dose Study of AMP945


    has successfully completed the dosing of subjects in the Single Ascending Dose (SAD) component of
    the Phase 1 clinical trial of its proprietary focal adhesion kinase (FAK) inhibitor AMP945.
    The Single Ascending Dose study involved four cohorts of healthy volunteers. The last cohort of
    volunteers received the highest single dose of AMP945 administered to date and achieved drug
    exposures corresponding to the maximum allowable level specified in the trial design. As noted for
    prior cohorts, the highest single dose AMP945 was found to be well tolerated and no safety concerns
    were identified.
    Last month, Amplia announced that it had started dosing subjects for the Multiple Ascending Dose
    (MAD) component of its Phase 1 trial. The Company remains on track to complete dosing and report
    top-line data from this trial in the June quarter. Dr John Lambert, CEO of Amplia commented: “We are
    very encouraged by the data that is coming in from this Phase 1 clinical study. Our focus is now on
    completing the trial in a timely manner, fully analysing the data and preparing for future clinical studies
    in patients with cancer and fibrosis.”
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.